Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Energy boosts Indian stock markets
Wed, 13 Jul 01:30 pm

Indian stock markets gained further ground during the previous two hours of trade. All sectoral indices are trading firm except Information Technology (IT) index. Stocks from the consumer durables, oil & gas, and auto are the biggest gainers.

The BSE-Sensex is trading up by 145 points while NSE-Nifty is trading 47 points above the dotted line. The BSE Midcap and BSE Small cap indices are up by 1.0% and 0.9% each. The rupee is trading at 44.55 to the US dollar.

Most of the pharma stocks are currently trading firm with Dr Reddy's Laboratories, Glenmark Pharma and Elder Pharma leading the pack of gainers. However, IPCA Labs and Cipla are trading weak. As per a leading financial daily, Dr Reddy's Laboratories (DRL) has received final approval from US Food and Drugs Administration (FDA) to sell Fondaparinux Sodium injection. The latter is used for the treatment and prevention of deep vein thrombosis (DVT). As per the management, it is a complex generic molecule and difficult to manufacture at a large scale. Hence, the company foresees a limited competition for the drug in the near future. It plans to leverage this opportunity. It plans to execute a phased launch in select wholesale and retail outlets, and subsequently enhance share over time in the coming quarters. DRL will manufacture the injection under license using a patented process developed by Australia's Alchemia. Dr Reddy's Fondaparinux Sodium injection is a generic version of GlaxoSmithKline's Arixtra. Arixtra sales grew 16% year-on-year to US$ 340 m for the 12 months ending May 2011.

Realty stocks are trading mixed led by Lok Housing and Constructions, Sobha Developers and Ansal Properties and Infrastructure. However, Godrej Properties, IVRCL Assets and Holdings and Unitech are trading weak. As per a leading financial daily, the Shiv Nadar-controlled HCL Group plans to acquire a substantial stake in DLF Pramerica Life Insurance Company Limited. The deal with real estate major DLF on this acquisition is in the advance stages of discussion. The deal size is estimated to be around Rs 4.5 bn. This acquisition would be the first non-IT diversification for the group.

At present, DLF holds 74% stake in the joint venture with Prudential Financial, the second-largest life insurer in the US. Therefore, the deal may face regulatory hurdle. As per the current guidelines, the original partner in a life insurance joint venture cannot sell its stake in the company during the first ten years of operations. The stock of DLF is currently trading firm.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Energy boosts Indian stock markets". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.